Chris Viehbacher, new Chairman of PhRMA made the point to his audience that "regulatory risk" is among the steepest hurdles facing the biopharmaceutical industry in the US.
Regulatory Risk Remains a Key Theme for Biopharma CEOs in 2011.
Viehbacher specifically cited the FDA and the need for the agency to stay abreast of the rapidly evolving science of new drugs from a regulatory perspective. "We need predictability from the agency" -- presumably in the evaluation and approval process.
Viehbacher said PhRMA will focus on the 3 T's going forward: transparency, truth and trust. "We have allies. We don't have a lot of them but we have them. They're not going to be interested in earnings per share."
Posted by Bruce Lehr April 14th 2011.
Comments